Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
Xilio Therapeutics, Inc. announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024. The company focuses on discovering and developing tumor-activated immuno-oncology therapies for cancer patients. The event will be live webcasted and accessible through the company's website, with a replay available for 30 days.
01/31/2024 - 04:01 PM
WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 pm EST.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/ . A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary geographically precise solutions (GPS) platform to build a pipeline of novel, tumor-activated molecules, including antibodies, cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc. ).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
What is the date of the Guggenheim 6th Annual Biotechnology Conference fireside chat?
The fireside chat will take place on February 7, 2024.
Who will participate in the fireside chat at the Guggenheim 6th Annual Biotechnology Conference?
René Russo, Pharm.D., president and chief executive officer of Xilio Therapeutics, Inc.
What is the focus of Xilio Therapeutics, Inc.?
The company focuses on discovering and developing tumor-activated immuno-oncology therapies for people living with cancer.
Where can the live webcast of the event be accessed?
The live webcast can be accessed under 'Events & Presentations' in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/.
How long will the replay of the webcast be available on the website?
The replay of the webcast will be archived on the website for 30 days following the presentation.
Xilio Therapeutics Inc
NASDAQ:XLO
XLO Rankings
#2791 Ranked by Stock Gains
XLO Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About XLO
xilio is a waltham, massachusetts-based biopharmaceutical company focused on defeating cancer. the company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, xilio, derived from the latin term, ex nihilo, meaning creation or big-bang. xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. to learn more, please visit www.xiliotx.com.
